Publications

Girotti MR, Gremel G, Lee R, Galvani E, Rothwell D, Viros A, Mandal AK, Lim KH, Saturno G, Furney SJ, Baenke F, Pedersen M, Rogan J, Swan J, Smith M, Fusi A, Oudit D, Dhomen N, Brady G, Lorigan P, Dive C, Marais R. (2016) Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. Cancer Discovery 6(3):286-99.

Baenke F, Chaneton B, Smith M, Van Den Broek N, Hogan K, Tang H, Viros A, Martin M, Galbraith L, Girotti MR, Dhomen N, Gottlieb E, Marais R. (2016) Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells. Molecular Oncology 10(1):73-84.

Conde-Perez A, Gros G, Longvert C, Pedersen M, Petit V, Aktary Z, Viros A, Gesbert F, Delmas V, Rambow F, Bastian BC, Campbell AD, Colombo S, Puig I, Bellacosa A, Sansom O, Marais R, Van Kempen LC, Larue L. (2015) A caveolin-dependent and PI3K/AKT-independent role of PTEN in β-catenin transcriptional activity. Nature Communications 6:8093.

Hirata E, Girotti MR, Viros A, Hooper S, Spencer-Dene B, Matsuda M, Larkin J, Marais R, Sahai E. (2015) Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling. Cancer Cell 27(4):574-88.

Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L, Whittaker S, Saturno G, Viros A, Pedersen M, Suijkerbuijk BM, Menard D, McLeary R, Johnson L, Fish L, Ejiama S, Sanchez-Laorden B, Hohloch J, Carragher N, Macleod K, Ashton G, Marusiak AA, Fusi A, Brognard J, Frame M, Lorigan P, Marais R, Springer C. (2015) Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell 27(1):85-96.

Viros A, Marais R. (2014) Hooked on UVR. Pigment Cell & Melanoma Research 27(6):1009-10.

Pedersen M*, Viros A*, Cook M, Marais R. (2014) (G12D) NRAS and kinase-dead BRAF cooperate to drive naevogenesis and melanomagenesis. Pigment Cell & Melanoma Research 27(6):1162-6. *Authors starred contributed equally

Orgaz JL, Pandya P, Dalmeida R, Karagiannis P, Sanchez-Laorden B, Viros A, Albrengues J, Nestle FO, Ridley AJ, Gaggioli C, Marais R, Karagiannis SN, Sanz-Moreno V. (2014) Diverse matrix metalloproteinase functions regulate cancer amoeboid migration. Nature Communications 5:4255.

Viros A*, Sanchez-Laorden B*, Pedersen M*, Furney SJ*, Rae J, Hogan K, Ejiama S, Girotti MR, Cook M, Dhomen N, Marais R. (2014) Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53. Nature 511(7510):478-82.*Authors starred contributed equally

Berta Sanchez-Laorden, Amaya Viros, Maria R Girotti, Richard Marais. (2014) BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Science Signaling 7(318):ra30.

Sanchez-Laorden B, Viros A, Marais R. (2013) Mind the IQGAP. Cancer Cell 23(6):715-7.

Wee JS, Viros A, Ffolkes L, Misch K, Natkunarajah J. (2013) Keratosis lichenoides chronica masquerading as discoid lupus erythematosus. Clinical and Experimental Dermatology 38(3):327-9.

Pedersen M*, Küsters-Vandevelde HV*, Viros A, Groenen PJ, Sanchez-Laorden B, Gilhuis JH, van Engen-van Grunsven IA, Renier W, Schieving J, Niculescu-Duvaz I, Springer CJ, Küsters B, Wesseling P, Blokx WA, Marais R. (2013) Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes. Cancer Discovery 3(4):458-69. *Authors starred contributed equally

Viros A, Hayward R, Martin M, Yashar S, Yu CC, Sanchez-Laorden B, Zambon A, Niculescu-Duvaz D, Springer C, Lo RS, Marais R. (2013)Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma. Journal of Investigative Dermatology 133(1):274-6.

Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, Zambon A, Sinclair J, Hayes A, Gore M, Lorigan P, Springer CJ, Larkin J, Jorgensen C, Marais R. (2012) Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discovery 3(2):158-67.

Martin MJ, Hayward R, Viros A, Marais R. (2012) Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discovery 2(4):344-55.

Su F*, Viros A*, Milagre C*, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R. (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. New England Journal of Medicine 366(3):207-15.*Authors starred contributed equally

Cañueto J, Girós M, Ciria S, Pi-Castán G, Artigas M, García-Dorado J, García-Patos V, Virós A, Vendrell T, Torrelo A, Hernández-Martín A, Martín-Hernández E, Garcia-Silva MT, Fernández-Burriel M, Rosell J, Tejedor M, Martínez F, Valero J, García JL, Sánchez-Tapia EM, Unamuno P, González-Sarmiento R. (2012) Clinical, molecular and biochemical characterization of nine Spanish families with Conradi-Hünermann-Happle syndrome: new insights into X-linked dominant chondrodysplasia punctata with a comprehensive review of the literature. British Journal of Dermatology 166(4):830-8.

Rae J, Viros A, Hayward R, Bennett DC, Dhomen N, Longley BJ, Reis-Filho JS, Marais R.  (2012) (V600E)Braf::Tyr-CreERT2::K14-Kitl mice do not develop superficial spreading-like melanoma: keratinocyte Kit ligand is insufficient to "translocate" (V600E)Braf-driven melanoma to the epidermis. Journal of Investigative Dermatology 132(2):488-91.

Sanz-Moreno V, Gaggioli C, Yeo M, Albrengues J, Wallberg F, Viros A, Hooper S, Mitter R, Féral CC, Cook M, Larkin J, Marais R, Meneguzzi G, Sahai E, Marshall CJ. (2011) ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell 20(2):229-45.

Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, Harrington KJ, Marais R, Nutting CM. (2011) Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. European Journal of Endocrinology 165(2):315-22.

Arozarena I, Sanchez-Laorden B, Packer L, Hidalgo-Carcedo C, Hayward R, Viros A, Sahai E, Marais R. (2011) Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell 19(1):45-57.

Whittaker S, Kirk R, Hayward R, Zambon A, Viros A, Cantarino N, Affolter A, Nourry A, Niculescu-Duvaz D, Springer C, Marais R. (2010) Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Science Translational Medicine 2(35):35ra41.

Handolias D, Salemi R, Murray W, Tan A, Liu W, Viros A, Dobrovic A, Kelly J, McArthur GA. (2010) Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell & Melanoma Research 23(2):210-5.

Aparicio G, Mollet J, Bartralot R, Bodet D, Heras C, Bassas P, Virós A, García-Patos V. (2008) Eruptive juvenile xanthogranuloma associated with relapsing acute lymphoblastic leukemia. Pediatric Dermatology 25(4):487-8.

Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D, Bastian BC. (2008) Improving melanoma classification by integrating genetic and morphologic features. PLoS Medicine 5(6):e120.

Delmas V, Beermann F, Martinozzi S, Carreira S, Ackermann J, Kumasaka M, Denat L, Goodall J, Luciani F, Viros A, Demirkan N, Bastian BC, Goding CR, Larue L. (2007) Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes & Development 21(22):2923-35.

Viros A, Garcia-Patos V, Aparicio G, Tallada N, Bastida P, Castells A. (2005) Sterile neonatal pustulosis associated with transient myeloproliferative disorder in twins. Archives of Dermatology 141(8):1053-4.